Pharmaceutical company Glaukos Corp. (GKOS) announced Thursday the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg.
Glaukos Corp. (GKOS) shares are gaining more than 9 percent on Thursday morning trade after the company announced FDA approval of its new drug application or NDA for a single administration per eye of iDose TR 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Glaukos (NYSE:GKOS – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. A number of other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their target price on Glaukos from $71.00 to $66.00 […]
Truist Financial started coverage on shares of Glaukos (NYSE:GKOS – Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $88.00 price target on the medical instruments supplier’s stock. A number of other research firms have also commented on GKOS. Mizuho lifted their price objective on shares […]
Truist Financial initiated coverage on shares of Glaukos (NYSE:GKOS – Free Report) in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $88.00 target price on the medical instruments supplier’s stock. GKOS has been the topic of several other reports. Mizuho raised their price objective on shares […]